Dolby Laboratories Financial Statements (DLB)
|
|
|
|
Report date
|
|
|
30.09.2022 |
18.11.2022 |
17.11.2023 |
19.11.2024 |
18.11.2025 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 254 |
1 254 |
1 300 |
1 274 |
1 349 |
|
1 365 |
|
Operating Income, bln rub |
|
|
206.6 |
217.2 |
262.8 |
264.7 |
265.0 |
|
254.6 |
|
EBITDA, bln rub |
? |
|
320.9 |
318.9 |
345.6 |
399.8 |
378.6 |
|
376.4 |
|
Net profit, bln rub |
? |
|
184.1 |
184.1 |
200.7 |
261.8 |
255.0 |
|
243.6 |
|
|
OCF, bln rub |
? |
|
318.6 |
318.6 |
367.1 |
327.3 |
472.2 |
|
337.8 |
|
CAPEX, bln rub |
? |
|
47.9 |
59.5 |
30.3 |
30.0 |
41.9 |
|
42.7 |
|
FCF, bln rub |
? |
|
270.6 |
259.1 |
336.7 |
297.2 |
430.3 |
|
295.1 |
|
Dividend payout, bln rub
|
|
|
100.1 |
100.1 |
103.4 |
114.6 |
126.6 |
|
131.9 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
54.4% |
54.4% |
51.5% |
43.8% |
49.6% |
|
54.1% |
|
|
OPEX, bln rub |
|
|
905.8 |
895.2 |
884.4 |
868.5 |
924.0 |
|
938.8 |
|
Cost of production, bln rub |
|
|
141.4 |
141.4 |
152.6 |
140.5 |
160.1 |
|
171.5 |
|
R&D, bln rub |
|
|
261.2 |
261.2 |
271.5 |
263.7 |
261.8 |
|
266.2 |
|
Interest expenses, bln rub |
|
|
0.394 |
0.000 |
0.000 |
0.000 |
0.000 |
|
4.12 |
|
|
Assets, bln rub |
|
|
2 690 |
2 702 |
2 995 |
3 131 |
3 228 |
|
3 249 |
|
Net Assets, bln rub |
? |
|
2 246 |
2 246 |
2 355 |
2 477 |
2 623 |
|
2 618 |
|
Debt, bln rub |
|
|
50.9 |
50.9 |
50.6 |
47.0 |
38.9 |
|
49.7 |
|
Cash, bln rub |
|
|
809.3 |
817.6 |
957.1 |
577.8 |
702.6 |
|
594.7 |
|
Net debt, bln rub |
|
|
-758.4 |
-766.6 |
-906.5 |
-530.8 |
-663.7 |
|
-545.1 |
|
|
Ordinary share price, rub |
|
|
65.2 |
65.2 |
79.3 |
75.6 |
72.4 |
|
83.5 |
|
Number of ordinary shares, mln |
|
|
100.0 |
100.0 |
95.8 |
95.5 |
95.9 |
|
95.2 |
|
|
Market cap, bln rub |
|
|
6 514 |
6 514 |
7 593 |
7 224 |
6 940 |
|
7 946 |
|
EV, bln rub |
? |
|
5 756 |
5 748 |
6 686 |
6 693 |
6 276 |
|
7 401 |
|
Book value, bln rub |
|
|
2 246 |
1 769 |
1 779 |
1 509 |
1 696 |
|
1 699 |
|
|
EPS, rub |
? |
|
1.84 |
1.84 |
2.09 |
2.74 |
2.66 |
|
2.56 |
|
FCF/share, rub |
|
|
2.71 |
2.59 |
3.52 |
3.11 |
4.49 |
|
3.10 |
|
BV/share, rub |
|
|
22.5 |
17.7 |
18.6 |
15.8 |
17.7 |
|
17.8 |
|
|
EBITDA margin, % |
? |
|
25.6% |
25.4% |
26.6% |
31.4% |
28.1% |
|
27.6% |
|
Net margin, % |
? |
|
14.7% |
14.7% |
15.4% |
20.6% |
18.9% |
|
17.9% |
|
FCF yield, % |
? |
|
4.15% |
3.98% |
4.44% |
4.11% |
6.20% |
|
3.71% |
|
ROE, % |
? |
|
8.20% |
8.20% |
8.52% |
10.6% |
9.72% |
|
9.31% |
|
ROA, % |
? |
|
6.84% |
6.81% |
6.70% |
8.36% |
7.90% |
|
7.50% |
|
|
P/E |
? |
|
35.4 |
35.4 |
37.8 |
27.6 |
27.2 |
|
32.6 |
|
P/FCF |
|
|
24.1 |
25.1 |
22.5 |
24.3 |
16.1 |
|
26.9 |
|
P/S |
? |
|
5.20 |
5.20 |
5.84 |
5.67 |
5.14 |
|
5.82 |
|
P/BV |
? |
|
2.90 |
3.68 |
4.27 |
4.79 |
4.09 |
|
4.68 |
|
EV/EBITDA |
? |
|
17.9 |
18.0 |
19.3 |
16.7 |
16.6 |
|
19.7 |
|
Debt/EBITDA |
|
|
-2.36 |
-2.40 |
-2.62 |
-1.33 |
-1.75 |
|
-1.45 |
|
|
R&D/CAPEX, % |
|
|
544.9% |
439.3% |
895.0% |
878.7% |
624.2% |
|
623.3% |
|
|
CAPEX/Revenue, % |
|
|
3.82% |
4.74% |
2.33% |
2.36% |
3.11% |
|
3.13% |
|
| Dolby Laboratories shareholders |
